MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412419 | Name: Pirsidomine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pirsidomine is a sydnonimine with direct vasodilating and nitric oxide-donating properties.

Chemical Structure

Pirsidomine
Pirsidomine
CAS#132722-74-8

Theoretical Analysis

MedKoo Cat#: 412419

Name: Pirsidomine

CAS#: 132722-74-8

Chemical Formula: C17H23N4O3

Exact Mass: 331.1770

Molecular Weight: 331.39

Elemental Analysis: C, 61.61; H, 7.00; N, 16.91; O, 14.48

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Pirsidomine; CAS936; CAS-936; CAS 936
IUPAC/Chemical Name
Sydnone imine, 3-(2,6-dimethyl-1-piperidinyl)-N-(4-methoxybenzoyl)-, cis-
InChi Key
AYZXTFJBZWCJHK-BETUJISGSA-N
InChi Code
InChI=1S/C17H23N4O3/c1-12-5-4-6-13(2)20(12)21(11-16(18)24-19-21)17(22)14-7-9-15(23-3)10-8-14/h7-13H,4-6H2,1-3H3,(H-,18,19)/t12-,13+
SMILES Code
[NH-]C1=C[N+](C(C2=CC=C(OC)C=C2)=O)(N3[C@H](C)CCC[C@@H]3C)=NO1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 331.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wainwright CL, Martorana PA. Pirsidomine, a novel nitric oxide donor, suppresses ischemic arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol. 1993;22 Suppl 7:S44-50. PMID: 7504768. 2: Martorana PA, Kettenbach B, Bohn H, Schönafinger K, Henning R. Antiischemic effects of pirsidomine, a new nitric oxide donor. Eur J Pharmacol. 1994 May 23;257(3):267-73. doi: 10.1016/0014-2999(94)90138-4. PMID: 8088346. 3: Bohn H, Martorana PA, Schönafinger K. Cardiovascular effects of the new nitric oxide donor, pirsidomine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs. Eur J Pharmacol. 1992 Sep 10;220(1):71-8. doi: 10.1016/0014-2999(92)90013-t. PMID: 1425982. 4: de Mey C, Breithaupt K, Seibert-Grafe M, Belz GG. Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed. Eur J Clin Pharmacol. 1994;46(4):295-9. doi: 10.1007/BF00194394. PMID: 7957511. 5: Arkonac BM, Kersten JR, Wynsen JC, Nijhawan N, Warltier DC. Differential hemodynamic effects of the nitric oxide donor pirsidomine in comparison to SIN-1, nitroprusside and nitroglycerin. Pharmacology. 1996 Feb;52(2):92-100. doi: 10.1159/000139372. PMID: 8851630. 6: Stengele E, Ruf G, Jähnchen E, Trenk D, Löffler K, Schulz W, Roskamm H. Short-term hemodynamic, anti-ischemic, and antianginal effects of pirsidomine, a new sydnonimine. Am J Cardiol. 1996 May 1;77(11):937-41. doi: 10.1016/s0002-9149(96)00006-9. PMID: 8644642. 7: Bassenge E, Zanzinger J. Effectiveness of an NO-releasing pirsidomine derivative on coronary conductance during long-term administration. J Cardiovasc Pharmacol. 1993;22 Suppl 7:S22-6. PMID: 7504764. 8: Ivanova K, Schaefer M, Drummer C, Gerzer R. Effects of nitric oxide- containing compounds on increases in cytosolic ionized Ca2+ and on aggregation of human platelets. Eur J Pharmacol. 1993 Jan 4;244(1):37-47. doi: 10.1016/0922-4106(93)90057-g. PMID: 8420790. 9: Ostrowski J, Stockhausen H, Kessler E, Gruber C, Schraven E, Herrmann C. Exogenous nitric oxide stress on endothelial cells and macrophages. J Cardiovasc Pharmacol. 1992;20 Suppl 12:S148-50. doi: 10.1097/00005344-199204002-00042. PMID: 1282953. 10: Schini VB, Bond R, Gao Y, Illiano S, Junquero DC, Mombouli JV, Nagao T, Smart F, Vanhoutte PM. The sydnonimine C87-3754 evokes endothelium-independent relaxations and prevents endothelium-dependent contractions in blood vessels of the dog. J Cardiovasc Pharmacol. 1993;22 Suppl 7:S10-6. PMID: 7504762.